Dasatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

  • Recurrent or persistent disease

• Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest dimension to be recorded) as ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan

  • Has ≥ 1 target lesion to assess response

    • Tumors within a previously irradiated field are considered non-target lesions unless progression is documented or a biopsy is obtained to confirm persistence ≥ 90 days following completion of radiotherapy
• Ineligible for a higher priority GOG protocol

• Must have received 1 prior platinum-based chemotherapeutic regimen containing carboplatin, cisplatin, or other organoplatinum compound for management of primary disease

  • Initial treatment may have included intraperitoneal therapy, high-dose therapy, consolidation therapy, non-cytotoxic agents, or extended therapy administered after surgical or non-surgical assessment
  • One additional cytotoxic regimen for recurrent or persistent disease allowed
  • Disease progression during therapy OR disease persistence after completion of therapy OR platinum-free interval < 12 months
• No active pleural or pericardial effusion of any grade

PATIENT CHARACTERISTICS:

• GOG performance status (PS) 0-2 (for patients who received 1 prior regimen) OR PS 0-1 (for patients who received 2 prior regimens)
• Able to swallow whole pills
• ANC ≥ 1,500/mcL
• Platelet count ≥ 100,000/mcL
• Hemoglobin ≥ 10 g/dL
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• SGOT ≤ 2.5 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN

• Magnesium, calcium, phosphate, potassium, and sodium corrected to normal

  • No hypokalemia or hypomagnesemia that cannot be corrected to normal
• PT/INR ≤ 1.5 times ULN
• PTT ≤ 1.5 times ULN
• Neuropathy (sensory and motor) ≤ grade 1
• QTc interval ≤ 450 msec on ECG
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for ≥ 4 weeks after completion of study treatment
• No active infection requiring antibiotics (except uncomplicated urinary tract infection)
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

• No history of cardiac disease, including any of the following:

  • Uncontrolled angina, congestive heart failure, or myocardial infarction within the past 6 months
  • Diagnosed congenital long QT syndrome
  • Clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)

• No history of significant bleeding disorder unrelated to cancer, including any of the following:

  • Bleeding diathesis, congenital or acquired, (e.g., von Willebrand's disease, acquired anti-factor VIII antibodies) within the past year
  • Significant gastrointestinal bleeding within the past 3 months

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Recovered from prior surgery, radiotherapy, or chemotherapy

• At least 7 days since prior drugs known to prolong the QT interval, including any of the following:

  • Quinidine, procainamide, disopyramide
  • Amiodarone, sotalol, ibutilide, dofetilide
  • Erythromycin, clarithromycin
  • Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
  • Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine

• At least 1 week since prior hormonal therapy directed at the malignant tumor

  • Concurrent hormone replacement therapy allowed
• At least 3 weeks since other prior therapy directed at the malignant tumor, including immunologic agents
• At least 6 weeks since prior monoclonal antibodies
• No prior dasatinib

• No prior noncytotoxic therapy for recurrent or persistent disease

  • Prior biologic (noncytotoxic) therapy as part of primary treatment regimen allowed
• No prior cancer treatment that contraindicates study treatment
• No prior radiotherapy to > 25% of marrow-bearing areas

• More than 5 years since prior radiotherapy to any portion of the abdominal cavity or pelvis other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer

  • Prior radiotherapy for localized cancer of the breast, head and neck, or skin is allowed provided it was completed more than 3 years ago and the patient remains free of recurrent or metastatic disease

• More than 5 years since prior chemotherapy for any abdominal or pelvic tumor other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer

  • Prior adjuvant chemotherapy for localized breast cancer allowed provided it was completed more than 3 years ago and the patient remains free of recurrent or metastatic disease
• At least 5 days since prior and no concurrent Hypericum perforatum (St. John's wort)
• At least 7 days since prior and no concurrent potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin)

• Concurrent warfarin for prophylaxis or treatment of thrombosis allowed

  • Concurrent low molecular weight heparin is allowed provided PT/INR ≤ 1.5
• No IV bisphosphonates during the first 8 weeks of study treatment
• No concurrent amifostine or other protective reagents
• No concurrent grapefruit juice
• No concurrent H2 blockers or proton pump inhibitors (e.g., famotidine, omeprazole)
• No other concurrent investigational agents